The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K+ channel opener

Yen Mei Lee, Mao Hsiung Yen, Yen Yen Peng, Jeon Rong Sheu, Yao Chang Chen, Ming Jyh Chang, Chen Yu Cheng

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

ATP-sensitive K+ (K(ATP)) channel openers have been shown to be a potential class of therapeutic agents for the control of cardiovascular diseases, including angina, arrhythmias, and hypertension. In this study, the pharmacological activity of 6-cyano-3S,4R-dihydro-2,2-dimethyl-2H-3-hydroxy-4-[5S-(1-hydroxymethyl)-2-oxo-1-pyrrolidinyl]-1-benzopyran ((-)-MJ-451), a synthetic K(ATP) opener, was evaluated in anesthetized rat models and in isolated rat thoracic rings. Results demonstrated that intravascular injection of (-)-MJ-451 (0.02, 0.05 and 0.1 mg/kg) produced an immediate, dose-related reduction in mean arterial blood pressure in anesthetized spontaneously hypertensive rats (SHR), which persisted for more than 3 h and was not accompanied by reflex tachycardia. The hemodynamic changes were completely abolished by pretreatment with glibenclamide (4 mg/kg, i.v. bolus), a selective K(ATP) channel blocker. In isolated thoracic aorta, (-)-MJ-451 (10 nM-3 μM) produced a concentration-dependent vasodilator effect on the phenylephrine (0.3 μM)-induced vasoconstriction. Moreover, (-)-MJ-451 relaxed the thoracic aorta contracted by low (5, 20 and 30 mM), but not high (40 and 60 mM) concentrations of extracellular potassium. In addition, (-)-MJ-451 showed cardioprotective effects in the rat model of 45-min left coronary artery occlusion followed by 1-h reperfusion. In myocardial ischemia, pretreatment with (-)-MJ-451 (2, 5 and 10 μg/kg, i.v. bolus) significantly reduced the incidence of ventricular fibrillation and the mortality, also reducing the total number of ventricular premature contractions, total duration of ventricular tachycardia and ventricular fibrillation. A significant reduction in infarct size was noted in three (-)-MJ-451 (2, 5 and 10 μg/kg)-treated groups. Also, the cardioprotective effects of (-)-MJ-451 were virtually abolished by pretreating the rats with glibenclamide (4 mg/kg, i.v. bolus). In conclusion, (-)-MJ-451, through opening the K(ATP) channel, exerted antihypertensive and cardioprotective effects. Therefore, it is suggested that (-)-MJ-451 has potential in the treatment of hypertension or acute myocardial infarction. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)151-160
Number of pages10
JournalEuropean Journal of Pharmacology
Volume397
Issue number1
DOIs
Publication statusPublished - May 26 2000

Keywords

  • Arrhythmias
  • Hypertension
  • K(ATP) channel
  • Myocardial ischemia
  • Reperfusion

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Fingerprint Dive into the research topics of 'The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K<sup>+</sup> channel opener'. Together they form a unique fingerprint.

Cite this